{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:14:06Z","timestamp":1772165646241,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:00:00Z","timestamp":1766620800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"DOI":"10.1186\/s12877-025-06689-9","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T12:16:39Z","timestamp":1766492199000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The effect of bisphosphonates on kidney function in osteoporotic geriatric patients with impaired renal function"],"prefix":"10.1186","volume":"25","author":[{"given":"Akarawin","family":"Tweekittikul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varalak","family":"Srinonprasert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4642-0401","authenticated-orcid":false,"given":"Unchana","family":"Sura-amonrattana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"6689_CR1","unstructured":"World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva: World Health Organization; 1994. (WHO technical report series; no. 843)."},{"issue":"4","key":"6689_CR2","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.1532-5415.1985.tb07117.x","volume":"33","author":"RD Lindeman","year":"1985","unstructured":"Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985;33(4):278\u201385.","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"6689_CR3","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359\u201381.","journal-title":"Osteoporos Int"},{"issue":"32","key":"6689_CR4","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.2174\/1381612033453640","volume":"9","author":"MJ Rogers","year":"2003","unstructured":"Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des. 2003;9(32):2643\u201358.","journal-title":"Curr Pharm Des"},{"issue":"6","key":"6689_CR5","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1681\/ASN.V1261164","volume":"12","author":"GS Markowitz","year":"2001","unstructured":"Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001;12(6):1164\u201372.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"6689_CR6","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1053\/j.ajkd.2006.02.189","volume":"47","author":"M Sauter","year":"2006","unstructured":"Sauter M, J\u00fclg B, Porubsky S, Cohen C, Fischereder M, Sitter T, et al. Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept? Am J Kidney Dis. 2006;47(6):1075\u201380.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"6689_CR7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2165\/00002018-199921050-00004","volume":"21","author":"N Zojer","year":"1999","unstructured":"Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf. 1999;21(5):389\u2013406.","journal-title":"Drug Saf"},{"issue":"11","key":"6689_CR8","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1038\/ki.2008.356","volume":"74","author":"MA Perazella","year":"2008","unstructured":"Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int. 2008;74(11):1385\u201393.","journal-title":"Kidney Int"},{"key":"6689_CR9","unstructured":"Novartis Pharma Stein AG. Reclast [prescribing information]. Stein: Novarits Pharma Stein AG; 2011."},{"key":"6689_CR10","unstructured":"Warner Chilcott Puerto Rico LLC. Actonel [prescribing information]. Puerto Rico: Warner Chilcott Puerto Rico LLC; 2011."},{"key":"6689_CR11","unstructured":"Roche Products Ltd. Bonviva [summary of product characteristics]. Welwyn Garden City: Roche Products Ltd; 2011."},{"key":"6689_CR12","unstructured":"Merck Sharp & Dohme Limited. Fosamax [summary of product characteristics]. Hoddesdon, Hertfordshire: Merck Sharp & Dohme Limited; 2011."},{"issue":"Suppl 3","key":"6689_CR13","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1007\/BF01623005","volume":"3","author":"DM Black","year":"1993","unstructured":"Black DM, Reiss TF, Nevitt MC, Cauley J, Karpf D, Cummings SR. Design of the fracture intervention trial. Osteoporos Int. 1993;3(Suppl 3):S29\u201339.","journal-title":"Osteoporos Int"},{"issue":"22","key":"6689_CR14","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","volume":"333","author":"UA Liberman","year":"1995","unstructured":"Liberman UA, Weiss SR, Br\u00f6ll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The alendronate phase III osteoporosis treatment study group. N Engl J Med. 1995;333(22):1437\u201343.","journal-title":"N Engl J Med"},{"issue":"5","key":"6689_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip intervention program study group. N Engl J Med. 2001;344(5):333\u201340.","journal-title":"N Engl J Med"},{"issue":"4","key":"6689_CR16","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1359\/jbmr.070112","volume":"22","author":"SA Jamal","year":"2007","unstructured":"Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res. 2007;22(4):503\u20138.","journal-title":"J Bone Miner Res"},{"issue":"11","key":"6689_CR17","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1007\/s00198-022-06499-4","volume":"33","author":"CW Fixen","year":"2022","unstructured":"Fixen CW, Fixen DR. Renal safety of Zoledronic acid for osteoporosis in adults 75 years and older. Osteoporos Int. 2022;33(11):2417\u201322.","journal-title":"Osteoporos Int"},{"issue":"1","key":"6689_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31\u201341.","journal-title":"Nephron"},{"issue":"19","key":"6689_CR19","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737\u201349.","journal-title":"N Engl J Med"},{"issue":"1","key":"6689_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1053\/j.ajkd.2012.06.016","volume":"61","author":"HS Kilbride","year":"2013","unstructured":"Kilbride HS, Stevens PE, Eaglestone G, Knight S, Carter JL, Delaney MP, et al. Accuracy of the MDRD (Modification of Diet in Renal Disease) study and CKD-EPI (CKD Epidemiology Collaboration) equations for estimation of GFR in the elderly. Am J Kidney Dis. 2013;61(1):57\u201366.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"6689_CR21","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/ndt\/gfw425","volume":"32","author":"H Pottel","year":"2017","unstructured":"Pottel H, Delanaye P, Schaeffner E, Dubourg L, Eriksen BO, Melsom T, et al. Estimating glomerular filtration rate for the full age spectrum from serum creatinine and cystatin C. Nephrol Dial Transplant. 2017;32(3):497\u2013507.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"6689_CR22","doi-asserted-by":"publisher","first-page":"564","DOI":"10.4158\/GL-2020-0524","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS\/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS- 2020 UPDATE EXECUTIVE SUMMARY. Endocr Pract. 2020;26(5):564\u201370.","journal-title":"Endocr Pract"},{"issue":"3","key":"6689_CR23","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.clnu.2015.03.001","volume":"34","author":"T Cederholm","year":"2015","unstructured":"Cederholm T, Bosaeus I, Barazzoni R, Bauer J, Van Gossum A, Klek S, et al. Diagnostic criteria for malnutrition - An ESPEN consensus statement. Clin Nutr. 2015;34(3):335\u201340.","journal-title":"Clin Nutr"},{"issue":"2","key":"6689_CR24","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1186\/cc5713","volume":"11","author":"RL Mehta","year":"2007","unstructured":"Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31.","journal-title":"Crit Care"},{"issue":"5","key":"6689_CR25","first-page":"303","volume":"5","author":"D Du Bois","year":"1989","unstructured":"Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 1989;5(5):303\u201311. discussion 12\u2009\u2013\u20093.","journal-title":"Nutrition"},{"issue":"1","key":"6689_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12882-017-0478-9","volume":"18","author":"T Shigematsu","year":"2017","unstructured":"Shigematsu T, Muraoka R, Sugimoto T, Nishizawa Y. Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials. BMC Nephrol. 2017;18(1):66.","journal-title":"BMC Nephrol"},{"issue":"12","key":"6689_CR27","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1359\/JBMR.050817","volume":"20","author":"PD Miller","year":"2005","unstructured":"Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res. 2005;20(12):2105\u201315.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"6689_CR28","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jbmr.1494","volume":"27","author":"DM Black","year":"2012","unstructured":"Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27(2):243\u201354.","journal-title":"J Bone Miner Res"},{"issue":"9671","key":"6689_CR29","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","volume":"373","author":"DM Reid","year":"2009","unstructured":"Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009;373(9671):1253\u201363.","journal-title":"Lancet"},{"key":"6689_CR30","doi-asserted-by":"crossref","unstructured":"KDIGO. 2024 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4s):S117\u2013S314.","DOI":"10.1016\/j.kint.2023.10.018"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-025-06689-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-025-06689-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-025-06689-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T10:11:18Z","timestamp":1766657478000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12877-025-06689-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6689"],"URL":"https:\/\/doi.org\/10.1186\/s12877-025-06689-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7024056\/v1","asserted-by":"object"}]},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval of the research protocol was obtained from Siriraj Institutional Review Board (SIRB) (COA no. Si 116\/2024). Providing this study was a low-risk study, the SIRB considered the protocol as an expedited category. Data retrieval from hospital databased was made anonymized and did not require consent, according to the policy at the hospital and SIRB. The SIRB is grounded in the foundational ethical principles embodied in the Declaration of Helsinki of 1964 and its subsequent revisions and the Belmont Report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1041"}}